136 related articles for article (PubMed ID: 30353064)
41. Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival.
El-Ghammaz AMS; Ben Matoug R; Elzimaity M; Mostafa N
Support Care Cancer; 2017 Oct; 25(10):3085-3093. PubMed ID: 28439725
[TBL] [Abstract][Full Text] [Related]
42. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
43. Translation, adaptation, and reliability of the Stanford Integrated Psychosocial Assessment for Transplantation in the Spanish population.
López-Lazcano AI; López-Pelayo H; Lligoña A; Sánchez N; Vilas-Riotorto V; Priego A; Sánchez-González R; Rodríguez-Urrutia A; Quesada-Franco M; Maldonado JR; Pintor L
Clin Transplant; 2019 Oct; 33(10):e13688. PubMed ID: 31392778
[TBL] [Abstract][Full Text] [Related]
44. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
[TBL] [Abstract][Full Text] [Related]
45. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
47. [Clinical Analysis of Efficacy and Prognosis in 300 Cases of Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation].
Zhang Y; Song ZY; Li YH; Lu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1979-1985. PubMed ID: 31839070
[TBL] [Abstract][Full Text] [Related]
48. Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
Ehrlich KB; Miller GE; Scheide T; Baveja S; Weiland R; Galvin J; Mehta J; Penedo FJ
Bone Marrow Transplant; 2016 Dec; 51(12):1594-1598. PubMed ID: 27427918
[TBL] [Abstract][Full Text] [Related]
49. Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
Yu SC; Huang HH; Li CC; Tang JL; Lee YH; Mao TL; Kuo KT; Lin CT; Liu JH; Ko BS; Yao M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1367-1373. PubMed ID: 28450182
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.
Hamilton BK; Law AD; Rybicki L; Abounader D; Dabney J; Dean R; Duong HK; Gerds AT; Hanna R; Hill BT; Jagadeesh D; Kalaycio ME; Lawrence C; McLellan L; Pohlman B; Sobecks RM; Bolwell BJ; Majhail NS
Bone Marrow Transplant; 2015 Sep; 50(9):1235-40. PubMed ID: 26030045
[TBL] [Abstract][Full Text] [Related]
51. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
52. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.
Chevallier P; Szydlo RM; Blaise D; Tabrizi R; Michallet M; Uzunov M; Fegueux N; Guilhot F; Lapusan S; Gratecos N; Cahn JY; Socié G; Yakoub-Agha I; Huynh A; Francois S; Bay JO; Maury S; Buzyn A; Contentin N; Mohty M
Biol Blood Marrow Transplant; 2012 Feb; 18(2):289-94. PubMed ID: 21781949
[TBL] [Abstract][Full Text] [Related]
53. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
54. Perceptions of Hematopoietic Stem Cell Transplantation and Coping Predict Emotional Distress During the Acute Phase After Transplantation.
Baliousis M; Rennoldson M; Dawson DL; Mills J; das Nair R
Oncol Nurs Forum; 2017 Jan; 44(1):96-107. PubMed ID: 27991602
[TBL] [Abstract][Full Text] [Related]
55. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
56. Spiritual absence and 1-year mortality after hematopoietic stem cell transplant.
Pereira DB; Christian LM; Patidar S; Bishop MM; Dodd SM; Athanason R; Wingard JR; Reddy VS
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1171-9. PubMed ID: 20227510
[TBL] [Abstract][Full Text] [Related]
57. Current trends in clinical studies of allogeneic hematopoietic stem cell transplantation.
Pilon S; Jedrysiak D; Sheppard D; Bredeson CN; Tay J; Allan DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):364-70. PubMed ID: 25445635
[TBL] [Abstract][Full Text] [Related]
58. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of centre and period effects in allogeneic haematopoietic stem cell transplantation in France.
Mesnil F; Jouet JP; Tuppin P; Vernant JP; Golmard JL
Bone Marrow Transplant; 2004 Oct; 34(7):645-51. PubMed ID: 15300230
[TBL] [Abstract][Full Text] [Related]
60. Pre-transplantation serum ferritin as a prognostic marker in allogeneic haemopoietic stem cell transplant patients in a tertiary care hospital in Malaysia.
Thambiah SC; George E; Samsudin IN; Hong LH; Chuo LL; Ramli N; Zakaria MZ
Natl Med J India; 2016; 29(3):136-140. PubMed ID: 27808061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
